Jatenzo Medicare Part D Coverage: Costs, Formulary Status, and How to Lower Your Copay

What Jatenzo Is and Why It Costs What It Does

Jatenzo is the only FDA-approved oral testosterone replacement therapy in capsule form, receiving approval in March 2019 for adult males with hypogonadism caused by specific medical conditions [1]. Unlike topical gels and injectable testosterone cypionate, Jatenzo is absorbed through the lymphatic system rather than first-pass liver metabolism, which is the pharmacologic reason it carries a distinct safety and pricing profile [2].

The average cash price sits near $900 per month. That figure reflects Jatenzo's patent-protected status and the absence of a generic equivalent as of mid-2026. Topical testosterone gel, by comparison, costs $30 to $80 per month in generic form. This price gap is exactly why Medicare Part D plans impose access controls on Jatenzo: they want prescribers to demonstrate that cheaper alternatives failed or are contraindicated before covering the branded oral formulation.

The FDA label specifies a starting dose of 237 mg taken twice daily with food, adjustable between 158 mg and 396 mg twice daily based on serum testosterone levels measured after dose initiation [1]. Dose titration matters for cost because all capsule strengths carry roughly the same retail price, meaning dose adjustments do not significantly change your monthly spend.

How Medicare Part D Formulary Placement Works for Jatenzo

Medicare Part D plans organize drugs into formulary tiers, and Jatenzo lands on Tier 3 or Tier 4 in the majority of plan formularies. Tier 3 (preferred brand) typically carries copays of $40 to $100 per prescription. Tier 4 (non-preferred brand or specialty) pushes that range to $100 to $400, or sometimes a percentage-based coinsurance of 25% to 33% of the drug's negotiated price [3].

You can check your specific plan's formulary placement through the Medicare Plan Finder tool at medicare.gov. Every Part D plan is required to publish its formulary, and the listing will show Jatenzo's tier, any prior authorization requirements, quantity limits, and step therapy rules.

A 2023 analysis published in the Journal of Managed Care & Specialty Pharmacy found that specialty-tier medications in Part D carried median out-of-pocket costs 4.3 times higher than preferred brand-tier drugs, with mean annual beneficiary spending of $3,468 for specialty-tier products versus $804 for preferred brands [4]. Where your plan places Jatenzo on this tier structure determines the majority of your cost exposure.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "We suggest that clinicians inform patients of the availability of testosterone therapy in different formulations, with discussion of the advantages and disadvantages of each formulation" [5]. This guideline language supports formulary exception requests when a specific formulation is medically necessary.

Prior Authorization and Step Therapy Requirements

Nearly all Part D plans require prior authorization before covering Jatenzo. The PA process typically requires your prescriber to document a confirmed diagnosis of hypogonadism with two morning serum testosterone levels below 300 ng/dL, along with clinical signs or symptoms [5]. Processing time runs 24 to 72 hours for standard requests.

Step therapy is the second barrier. Most plans mandate that you try and fail (or have a documented contraindication to) at least one first-line testosterone formulation before they will approve Jatenzo. The step therapy sequence usually looks like this:

Step 1: Generic topical testosterone gel or solution (AndroGel generic, Vogelxo) Step 2: Testosterone cypionate injection (generic, self-administered or clinic-based) Step 3: Branded oral or nasal formulations including Jatenzo

To satisfy step therapy documentation, your prescriber needs to record the specific reason the prior formulation was inadequate. Acceptable reasons typically include: skin reactions to topical products (contact dermatitis reported in 5.7% of testosterone gel users per the AndroGel prescribing information [6]), inability to maintain application site precautions for transference risk, needle phobia or injection site complications, and failure to achieve therapeutic testosterone levels (350 to 750 ng/dL) despite dose optimization.

Dr. Shalender Bhasin, Professor of Medicine at Harvard Medical School and lead author of the Endocrine Society testosterone guidelines, has noted: "The choice of testosterone formulation should be a shared decision that considers the patient's preferences, pharmacokinetics, cost, and the formulation-specific adverse effects" [5]. Documenting this shared decision-making process in the medical record strengthens a PA request.

What You Will Pay During Each Part D Coverage Phase

Medicare Part D has four cost-sharing phases in 2026, and your Jatenzo copay changes as you move through them [3].

Deductible phase. The standard Part D deductible is $590 in 2026. You pay 100% of the negotiated drug price until you reach this amount. If Jatenzo is your first fill of the year, one month's supply could satisfy the entire deductible.

Initial coverage phase. After the deductible, you pay your plan's copay or coinsurance for Jatenzo until combined spending (yours plus the plan's) reaches $5,030 in 2026. At a Tier 4 coinsurance rate of 33%, a $900 list-price drug with a negotiated price around $700 would cost you roughly $231 per fill during this phase.

Coverage gap (donut hole). Once you enter the gap, you are responsible for 25% of the negotiated price for brand-name drugs thanks to the Inflation Reduction Act provisions. For Jatenzo, that translates to approximately $175 per month, though the manufacturer's discount contribution counts toward moving you out of the gap [7].

Catastrophic coverage. After your true out-of-pocket spending hits $2,000 (the 2026 cap established by the Inflation Reduction Act), you pay $0 for the rest of the year [7]. This $2,000 annual cap is a significant change from prior years, where catastrophic-phase cost sharing continued indefinitely.

For a beneficiary filling Jatenzo every month at Tier 4 coinsurance of 33%, the math works out roughly as follows: you would hit the $2,000 out-of-pocket cap somewhere between month four and month six, depending on other medications. Every fill after that costs nothing for the remainder of the calendar year.

The Manufacturer Savings Program and Its Medicare Limitation

Tolmar, the manufacturer of Jatenzo, offers a copay savings card that can reduce out-of-pocket costs to as low as $0 for commercially insured patients, with a maximum annual benefit that has historically been set at $7,200 to $9,600 [8].

Here is the critical limitation: federal law prohibits the use of manufacturer copay cards with Medicare, Medicaid, TRICARE, and other federally funded insurance programs [9]. If you are a Medicare Part D beneficiary, you cannot use the Jatenzo copay card. This restriction exists under the Anti-Kickback Statute, which treats copay assistance on government-funded prescriptions as an illegal inducement.

The one narrow exception involves independent, third-party patient assistance foundations. These 501(c)(3) charitable organizations operate under an OIG advisory opinion framework and can legally provide copay assistance to Medicare beneficiaries. The HealthWell Foundation and the PAN Foundation have historically maintained funds for testosterone replacement therapy, though fund availability fluctuates and cannot be guaranteed for any specific period [10].

To check current fund status, contact these organizations directly:

• HealthWell Foundation: healthwellfoundation.org
• PAN Foundation: panfoundation.org
• NeedyMeds: needymeds.org (maintains a searchable database of all active disease-fund programs)

Extra Help (Low-Income Subsidy) and State Pharmaceutical Assistance

Medicare's Extra Help program, also called the Low-Income Subsidy (LIS), can reduce Jatenzo costs to between $0 and $11.20 per prescription in 2026 for qualifying beneficiaries [3]. Eligibility is based on income below 150% of the federal poverty level and limited financial resources.

Full LIS beneficiaries (those receiving full Medicaid or Supplemental Security Income) pay $0 for drugs below the generic threshold and $0 for drugs above it in 2026. Partial LIS beneficiaries pay a sliding-scale copay. Given Jatenzo's high list price, even partial LIS enrollment produces substantial savings compared to standard Part D cost-sharing.

Application is through the Social Security Administration (ssa.gov/medicare/part-d-extra-help) or your State Health Insurance Assistance Program (SHIP). Processing typically takes two to four weeks.

Several states also operate State Pharmaceutical Assistance Programs (SPAPs) that wrap around Medicare Part D. These programs vary widely: some cover copays, some provide supplemental formulary coverage, and some operate as premium assistance. The Medicare Rights Center maintains a state-by-state directory at medicarerights.org.

How to File a Formulary Exception Request

If your Part D plan places Jatenzo on a high cost-sharing tier or excludes it from the formulary entirely, you have the right to request a formulary exception under 42 CFR § 423.578 [11]. There are two types:

Formulary exception (requesting coverage of a non-formulary drug): Your prescriber must submit a statement explaining why all formulary alternatives are not appropriate for your medical condition.

Tier exception (requesting lower cost-sharing): Your prescriber must demonstrate that you have tried and failed the lower-tier alternatives, or that they are contraindicated.

The plan must respond within 72 hours for a standard request and 24 hours for an expedited request. If denied, you can appeal through five levels: plan-level redetermination, Independent Review Entity (IRE) reconsideration, Office of Medicare Hearings and Appeals (OMHA) ALJ hearing, Medicare Appeals Council, and federal district court [11].

A 2021 study in Health Affairs found that 73% of Part D coverage determination requests were initially approved, and among those initially denied, 48% were overturned on first-level appeal [12]. The data supports filing an appeal rather than accepting an initial denial. Your prescriber's supporting statement is the single most important document in this process: it should cite specific clinical contraindications, failed trials, or adverse effects with alternative formulations, referencing the Endocrine Society guidelines where applicable.

Comparing Jatenzo Costs to Other Testosterone Formulations Under Part D

Understanding relative pricing helps frame the step therapy discussion with your prescriber and can inform formulary exception arguments.

Generic testosterone cypionate injection (200 mg/mL, 10 mL vial) carries a cash price of $40 to $80 and sits on Tier 1 or Tier 2 of nearly every Part D formulary, with copays of $1 to $15 [6]. Generic topical testosterone gel 1% (pump or packets) runs $30 to $100 cash and occupies Tier 1 or Tier 2, with similar low copays.

Branded alternatives tell a different story. AndroGel 1.62% (branded) costs $500 to $700 per month cash and typically sits on Tier 3. Natesto (nasal testosterone) runs $600 to $800 per month and occupies Tier 3 or Tier 4. Jatenzo at $900 per month usually lands on Tier 3 or Tier 4 [8].

The clinical argument for Jatenzo over injections centers on two factors. First, the oral route avoids the supraphysiologic testosterone peaks and troughs seen with biweekly intramuscular injections, which can cause mood fluctuations and erythrocytosis. A phase 3 trial of Jatenzo (N=166) demonstrated that 87% of subjects achieved average testosterone concentrations within the normal range (300 to 1,100 ng/dL) at day 90, with a maximum mean concentration (Cavg) of 489 ng/dL, avoiding the >1,500 ng/dL spikes sometimes seen with injectable testosterone [2]. Second, oral administration eliminates transference risk to household contacts, which the FDA highlighted as a class-wide safety concern for all topical testosterone products in a 2009 safety communication [13].

Practical Steps to Minimize Your Jatenzo Cost on Medicare Part D

Start with plan selection during Annual Enrollment (October 15 to December 7). Use the Medicare Plan Finder and enter Jatenzo specifically as one of your medications. The tool will rank Part D plans by estimated annual cost, factoring in premiums, deductibles, and drug-specific cost-sharing. Plans vary dramatically: the difference between the lowest-cost and highest-cost plan for the same drug in the same ZIP code can exceed $2,000 annually [3].

If you are already enrolled in a plan, take these steps in order:

1. Confirm Jatenzo's formulary tier and restrictions on your plan's drug list
2. Ask your prescriber to submit prior authorization with full clinical documentation
3. If placed on a high tier, request a tier exception with a supporting prescriber statement
4. Apply for Extra Help if your income is below 150% of the federal poverty level
5. Search for independent charitable copay assistance through NeedyMeds or PAN Foundation
6. Ask your prescriber's office about any Tolmar-sponsored patient assistance programs for uninsured or underinsured patients (distinct from the copay card, which is Medicare-prohibited)

The $2,000 annual out-of-pocket cap under the Inflation Reduction Act means that even at full Tier 4 pricing, your total yearly Jatenzo spend on Part D will not exceed $2,000 [7]. For many beneficiaries taking multiple brand-name medications, this cap is reached within the first few months of the year, making every subsequent Jatenzo fill effectively free.